| B40 | Utilization of antiretroviral refill histories as a predictor of future HIV viremia | E-poster | Adherence measurement |
| B42 | Region-specific laboratory reference intervals are important: a review of the data from Africa | E-poster | Ethical issues in clinical trials and treatment strategies |
| B43 | Five years durability of dolutegravir + lamivudine in patients with suppressed HIV-RNA | E-poster | New strategies (2DR, rapid start) |
| B43 | Immediate versus delayed antiretroviral treatment in hospitalized persons with AIDS-defining opportunistic disease: a randomized clinical trial | E-poster | New strategies (2DR, rapid start) |
| B43 | Largely increasing amounts of patients under dual ART due to new therapeutic regimens: dual therapy regimens 2016-2020 in the German North Rhine Cohort | E-poster | New strategies (2DR, rapid start) |
| B43 | Feasibility, efficacy, and safety of Dolutegravir/Lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV (PLWH): 48-week results of the STAT study | E-poster | New strategies (2DR, rapid start) |
| B43 | 48 weeks efficacy and tolerability of dolutegravir (DTG) + lamivudine (3TC) in adult HIV naïve patients. A multicenter real life cohort | E-poster | New strategies (2DR, rapid start) |
| B43 | Immediate ART is feasible during the COVID-19 pandemic | E-poster | New strategies (2DR, rapid start) |
| B49 | Food rescue programs in food-insecure PWLH in Baylor Mwanza-Tanzania: a descriptive study | E-poster | Nutrition |
| B53 | Prevalence of depression among postpartum women on Isoniazid-Preventive Therapy and Efavirenz-based treatment for HIV'an exploratory objective of the IMPAACT P1078 randomized trial | E-poster | Pregnancy (clinical management issues and pharmacokinetics) |